The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Abstract
PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous comparisons of different dosing regimens [75, 76] revealed that trastuzumab or rituximab Cmax did not correlate with clinical efficacy.”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [76]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Self-citationCobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Self-citationHumanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P. M., Presta, L. G., Gorman, C., Ridgway, J. B., Henner, D. J., Wong, W., Rowland, A. M., Kotts, C. E., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,926
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. E. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 974
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 250
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I. O., Locker, A. P., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,009
Croessmann, S., Formisano, L., Kinch, L. N., Ericsson, P. I. G., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E., Cristofanilli, M., He, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1544 · Cited by 107
Altunay, B., Morgenroth, A., Beheshti, M., Vogg, A. T. J., Wong, N. C. L., Ting, H. H., Biersack, H., Stickeler, E., & Mottaghy, F. M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05094-1 · Cited by 110
Maria, R. D., Olivero, M., Iussich, S., NAKAICHI, M., Murata, T., BIOLATTI, B., & Renzo, M. F. D. (2005) · Cancer Research · doi:10.1158/0008-5472.907.65.3 · Cited by 108
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice
Ma, Y., Lespagnard, L., Durbecq, V., Paesmans, M., Desmedt, C., Gomez-Galdón, M., Veys, I., Cardoso, F., Sotiriou, C. P., Leo, A. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2256 · Cited by 108
Bevacizumab in the Treatment of Breast Cancer: Rationale and Current Data
Rugo, H. S. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-43 · Cited by 108
Apolone, G., Joppi, R., Bertelè, V., & Garattini, S. K. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602750 · Cited by 107
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 110
Salem, O., Erdem, N., Jung, J., Münstermann, E., Wörner, A., Wilhelm, H., Wiemann, S., & Körner, C. (2016) · BMC Genomics · doi:10.1186/s12864-016-2869-x · Cited by 105
Wiseman, S. M., Makretsov, N. A., Nielsen, T. O., Gilks, C. B., Yorida, E., Cheang, M. C. U., Turbin, D. A., Gelmon, K. A., & Huntsman, D. D. (2005) · Cancer · doi:10.1002/cncr.20970 · Cited by 106
Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules
Salvaña, E. M. T., & Salata, R. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-08 · Cited by 106
Barua, S., & Mitragotri, S. (2013) · ACS Nano · doi:10.1021/nn403913k · Cited by 105
Our changing view of the genomic landscape of cancer
Bell, D. W. (2009) · The Journal of Pathology · doi:10.1002/path.2645 · Cited by 109
Lennon, S., Barton, C. M., Banken, L., Gianni, L., Marty, M. E., Baselga, J. M., & Leyland-Jones, B. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.8351 · Cited by 103
Management of metastatic carcinoma of the uveal tract: an evidence‐based analysis
Kanthan, G. L., Jayamohan, J., Yip, D., & Conway, R. M. (2007) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2007.01550.x · Cited by 104
Synthetic lethal approaches to breast cancer therapy
Rehman, F. L., Lord, C. J., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.172 · Cited by 104
Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0742-t · Cited by 103
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V. M., Xu, L., Kohli, N., Rennard, R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 106
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend
Ferretti, G., Felici, A., Papaldo, P., Fabi, A., & Cognetti, F. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328012980a · Cited by 103
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Gown, A. M., Goldstein, L. C., Barry, T. S., Kussick, S. J., Kandalaft, P. L., Kim, P. M., & Tse, C. C. H. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.83 · Cited by 100
von Minckwitz, G., Harder, S., Hövelmann, S., Jäger, E., Al‐Batran, S., Loibl, S., Atmaca, A., Cimpoiasu, C., Antje, N., Abera, A., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1264 · Cited by 101
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Yeon, C. H., & Pegram, M. D. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2899-8 · Cited by 101
Pe, M. L., Dorme, L., Coens, C., Basch, E., Calvert, M., Campbell, A., Cleeland, C. S., Cocks, K., Collette, L., Dirven, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30418-2 · Cited by 101
Munzone, E., Nolè, F., Goldhirsch, A., Botteri, E., Espósito, A., Zorzino, L., Curigliano, G., Minchella, I., Adamoli, L., Cassatella, M. C., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.052 · Cited by 99
Han, T. H., & Zhao, B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058586 · Cited by 100
Rupp, U., Schoendorf-Holland, E., Eichbaum, M. H. R., Schütz, F., Lauschner, I., Schmidt, P., Staab, A., Hanft, G., Huober, J., Sinn, H., et al. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32801403f4 · Cited by 99
Roepman, P., Horlings, H. M., Krijgsman, O., Kok, M., Bueno-de-Mesquita, J. M., Bender, R. A., Linn, S. C., Glas, A. M., & van de Vijver, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0449 · Cited by 99
Biomolecular Condensates and Their Links to Cancer Progression
Cai, D., Liu, Z. J., & Lippincott‐Schwartz, J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.01.002 · Cited by 97
Anticancer therapy induced cardiotoxicity: review of the literature
Geiger, S., Lange, V., Suhl, P., Heinemann, V., & Stemmler, H. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283394624 · Cited by 100
Perez, E. A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0005-6 · Cited by 101
ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer
Hinohara, K., Kobayashi, S., Kanauchi, H., Shimizu, S., Nishioka, K., Tsuji, E.-I., Tada, K.-I., Umezawa, K., Mori, M., Ogawa, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113271109 · Cited by 99
Rayson, D., Richel, D. J., Chia, S., Jackisch, C., van der Vegt, S., & Suter, T. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn292 · Cited by 99
Mantarro, S., Rossi, M., Bonifazi, M., D’Amico, R., Blandizzi, C., Vecchia, C. L., Negri, E., & Moja, L. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1362-x · Cited by 101
Fumagalli, C., & Barberis, M. C. P. (2021) · Diagnostics · doi:10.3390/diagnostics11091555 · Cited by 97
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
Ling, Y., Liang, G., Lin, Q., Fang, X., Luo, Q., Cen, Y., Mehrpour, M., Hamaï, A., Liu, Z., Shi, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01476-7 · Cited by 97
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
Robbins, C. T., Fernandez, A. I., Han, G., Wong, S. T.-L., Harigopal, M., Podoll, M., Singh, K., Ly, A., Kuba, M. G., Wen, H. Y., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100032 · Cited by 98
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Colozza, M., de Azambuja, E., Personeni, N., Lebrun, F., Piccart, M. J., & Cardoso, F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-253 · Cited by 97
Riemer, A. B., Klinger, M., Wagner, S. N., Bernhaus, A., Mazzucchelli, L., Pehamberger, H., Scheiner, O., Zielinski, C. C., & Jensen‐Jarolim, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.1.394 · Cited by 97
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
Fessler, S. P., Wotkowicz, M. T., Mahanta, S. K., & Bamdad, C. C. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0412-3 · Cited by 96
Nahta, R., & O'Regan, R. M. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.s.015 · Cited by 95
Ghislain, I., Zikos, E., Coens, C., Quinten, C., Balta, V., Tryfonidis, K., Piccart, M. J., Zardavas, D., Nagele, E., Bjelic‐Radisic, V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30099-7 · Cited by 96
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs
Spänkuch, B., Kurunci‐Csacsko, E., Kaufmann, M., & Strebhardt, K. (2007) · Oncogene · doi:10.1038/sj.onc.1210355 · Cited by 96
Non‐invasive molecular imaging for preclinical cancer therapeutic development
O’Farrell, A. C., Shnyder, S. D., Marston, G., Coletta, P. L., & Gill, J. H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12155 · Cited by 96
Yu, X., Ghamande, S. A., Liu, H., Xue, L., Zhao, S., Tan, W., Zhao, L., Tang, S.-C., Wu, D., Körkaya, H., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.12.015 · Cited by 96
Plasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification
Iliuk, A. B., Wu, X., Li, L., Sun, J., Hadisurya, M., Boris, R. S., & Tao, W. A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00151 · Cited by 93
Lin, N., Pegram, M. D., Sahebjam, S., Ibrahim, N. K., Fung, A., Cheng, A., Nicholas, A., Kirschbrown, W. P., & Kumthekar, P. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02822 · Cited by 95
Azémar, M., Djahansouzi, S., Jäger, E., Solbach, C., Schmidt, M., Maurer, A. B., Mross, K. B., Unger, C., von Minckwitz, G., Dall, P., et al. (2003) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000004371.48757.19 · Cited by 95
Targeting ErbB receptor signaling: A pan-ErbB approach to cancer
Britten, C. D. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1335.3.10 · Cited by 95
Chen, G., Gupta, R., Petrik, S., Laiko, M., Leatherman, J. M., Asquith, J. M., Daphtary, M. M., Garrett-Mayer, E. S., Davidson, N. E., Hirt, K., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0058 · Cited by 95
Niepel, M., Hafner, M. A., Pace, E. A., Chung, M., Chai, D. H., Zhou, L., Schoeberl, B., & Sorger, P. K. (2013) · Science Signaling · doi:10.1126/scisignal.2004379 · Cited by 93
Perspectives of HER2-targeting in gastric and esophageal cancer
Gerson, J. N., Skariah, S., Denlinger, C. S., & Astsaturov, I. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1315406 · Cited by 93
Trastuzumab and breast cancer: developments and current status
Tokunaga, E., Oki, E., Nishida, K., Koga, T., Egashira, A., Morita, M., Kakeji, Y., & Maehara, Y. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0575-4 · Cited by 94
Toi, M., Iwata, H., Fujiwara, Y., Ito, Y., Nakamura, S., Tokuda, Y., Taguchi, T., Rai, Y., Aogi, K., Arai, T., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605343 · Cited by 93
Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer
Howe, L. R., & Brown, P. H. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0334 · Cited by 93
Pan, C.-X., Zhang, H., Tepper, C. G., Lin, T., Davis, R. R., Keck, J., Ghosh, P., Gill, P. S., Airhart, S. D., Bult, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134346 · Cited by 94
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours
Kucab, J. E., Lee, C., Chen, C., Zhu, J., Gilks, C. B., Cheang, M. C. U., Huntsman, D. D., Yorida, E., Emerman, J. T., Pollak, M., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1294 · Cited by 92
Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2–Positive Breast Cancer
Roy, V., & Perez, E. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0142 · Cited by 92
Wu, Z., Yang, K., Wan, Y., Qian, P., Perry, J. K., Chiésa, J., Mertani, H. C., Zhu, T., & Lobie, P. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1245 · Cited by 92
Second consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J. M., Burstein, H. J., Cocquyt, V. F. J., Gnant, M., Goodwin, P. J., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl155 · Cited by 92
Self-citationConlin, A. K., Seidman, A. D., Bach, A. M., Lake, D. E., Dickler, M. N., D’Andrea, G. M., Traina, T. A., Danso, M. A., Brufsky, A., Saleh, M. N., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.036 · Cited by 91
Hou, Y., Nitta, H., Wei, L., Banks, P. M., Portier, B. P., Parwani, A. V., & Li, Z. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4453-8 · Cited by 91
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 95
Targeting the Hippo Pathway for Breast Cancer Therapy
Wu, L., & Yang, X. (2018) · Cancers · doi:10.3390/cancers10110422 · Cited by 92
Shi, Y., Huang, W., Tan, Y., Jin, X., Dua, R., Penuel, E. M., Mukherjee, A., Sperinde, J., Pannu, H., Chenna, A., et al. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31818cbdb2 · Cited by 91
Novel antibodies as anticancer agents
Zafir‐Lavie, I., Michaeli, Y., & Reiter, Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210372 · Cited by 100
El‐Deiry, W. S., Vijayvergia, N., Xiu, J., Scicchitano, A., Lim, B., Yee, N. S., Harvey, H. A., Gatalica, Z., & Reddy, S. K. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1113356 · Cited by 91
Kauraniemi, P., Kuukasjärvi, T., Sauter, G., & Kallioniemi, A. H. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63556-0 · Cited by 91
Selective Permeabilization of the Blood–Brain Barrier at Sites of Metastasis
Connell, J. J., Chatain, G. P., Cornelissen, B. T., Vallis, K. A., Hamilton, A., Seymour, L. W., Anthony, D. C., & Sibson, N. R. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt276 · Cited by 90
Evolution of anti-HER2 therapies for cancer treatment
Parakh, S., Gan, H. K., Parslow, A. C., Burvenich, I. J. G., Burgess, A. W., & Scott, A. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.005 · Cited by 89
Personalized medicine in breast cancer: pharmacogenomics approaches
Jeibouei, S., Akbari, M. E., Kalbasi, A., Aref, A. R., Ajoudanian, M., Rezvani, A., & Zali, H. (2019) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s167886 · Cited by 108
Sawaki, M., Taira, N., Uemura, Y., Saito, T., Baba, S., Kobayashi, K., Kawashima, H., Tsuneizumi, M., Sagawa, N., Bando, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00184 · Cited by 102
Inoue, K., Nakagami, K., Mizutani, M., Hozumi, Y., Fujiwara, Y., Masuda, N., Tsukamoto, F., Saito, M., Miura, S., Eguchi, K., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0498-7 · Cited by 89
Kinases as targets in the treatment of solid tumors
Giamas, G., Man, Y. L., Hirner, H., Bischof, J., Kramer, K. M., Khan, K., Ahmed, S. S. L., Stebbing, J., & Knippschild, U. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.011 · Cited by 88
Dokmanovic, M., Hirsch, D. S., Shen, Y., & Wu, W. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0140 · Cited by 90
Feldinger, K., Generali, D., Krämer-Marek, G., Gijsen, M., Ng, T. B., Wong, J. H., Strina, C., Cappelletti, M., Andreis, D., Li, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1955 · Cited by 88
NK cells-directed therapies target circulating tumor cells and metastasis
Dianat‐Moghadam, H., Mahari, A., Heidarifard, M., Parnianfard, N., Pourmousavi-Kh, L., Rahbarghazi, R., & Amoozgar, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.021 · Cited by 89
Tumour molecular profiling for deciding therapy—the French initiative
Nowak, F., Soria, J., & Calvo, F. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.42 · Cited by 87
Ali, S. M., Carney, W. P., Esteva, F. J., Fornier, M. N., Harris, L. N., Köstler, W. J., Lotz, J., Lüftner, D., Pichon, M. F., & Lipton, A. (2008) · Cancer · doi:10.1002/cncr.23689 · Cited by 87
Self-citationHer-2/neu and Topoisomerase iiα in Breast Cancer
Järvinen, T. A. H., & Liu, E. T. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023077507295 · Cited by 87
de Candia, P., Solit, D. B., Giri, D. D., Brogi, E., Siegel, P. M., Olshen, A. B., Muller, W. J., Rosen, N. X., & Benezra, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2031337100 · Cited by 86
Willis, A. L., Tran, N. L., Chatigny, J. M., Charlton, N., Vu, H., Brown, S. A. N., Black, M. A., McDonough, W. S., Ensign, S. P. F., Niska, J. R., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0005 · Cited by 87
Saxena, R., & Dwivedi, A. (2010) · Medicinal Research Reviews · doi:10.1002/med.20209 · Cited by 88
Fadden, P., Huang, K. H., Veal, J. M., Steed, P. M., Barabasz, A. F., Foley, B. E., Hu, M., Partridge, J. M., Rice, J. W., Scott, A., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.015 · Cited by 86
Garton, A. J., Crew, A. P. A., Franklin, M. R., Cooke, A. R., Wynne, G. M., Castaldo, L., Kahler, J., Winski, S. L., Franks, A., Brown, E. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2873 · Cited by 86
Kalous, O., Conklin, D. F., Desai, A. J., O’Brien, N. A., Ginther, C., Anderson, L. A., Cohen, D. J., Britten, C. D., Taylor, I. W., Christensen, J. G., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0730 · Cited by 84
Self-citationPrognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
Kountourakis, P., Pavlakis, K., Psyrri, A. K., Rontogianni, D. P., Xiros, N., Patsouris, E., Pectasides, D. G., & Economopoulos, T. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-46 · Cited by 85
Peddi, P. F., & Hurvitz, S. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014539183 · Cited by 84
Gastric cancer and the epoch of immunotherapy approaches
Niccolai, E., Taddei, A., Prisco, D., & Amedei, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5778 · Cited by 84
Pan, A., Wang, Z., Chen, B., Dai, W., Zhang, H., He, B., Wang, X., Wang, Y., & Zhang, Q. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474971 · Cited by 85
Blood transcriptomics and metabolomics for personalized medicine
Li, S., Todor, A., & Luo, R. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.10.005 · Cited by 86
da Costa, R. B., Kurra, G., Greenberg, L., & Geyer, C. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq096 · Cited by 84
Shah, M. V., Wiktor, A. E., Meyer, R. G., Tenner, K., Ballman, K. V., Green, S. J., Sukov, W. R., Ketterling, R. P., Perez, E. A., & Jenkins, R. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.8983 · Cited by 85
Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer
Kershaw, M. H., Jackson, J. T., Haynes, N. M., Teng, M. W. L., Moeller, M., Hayakawa, Y., Street, S. E. A., Cameron, R., Tanner, J. E., Trapani, J. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2143 · Cited by 84
Systematic Review of HER2 Breast Cancer Testing
Cuadros, M., & Villegas, R. (2008) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e318169fc1c · Cited by 84
Half, E., Broaddus, R. R., Danenberg, K. D., Danenberg, P. V., Ayers, G. D., & Sinicrope, F. A. (2003) · International Journal of Cancer · doi:10.1002/ijc.11599 · Cited by 84
Arens, N., Bleyl, U., & Hildenbrand, R. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1244-0 · Cited by 84
Critical analysis of the potential for microRNA biomarkers in breast cancer management
Sempere, L. F., Graveel, C. R., Calderone, H. M., Westerhuis, J. J., & Winn, M. E. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s43799 · Cited by 84
Shah, C., Miller, T. W., Wyatt, S. K., McKinley, E. T., Olivares, M. G., Sanchez, V. M., Nolting, D. D., Buck, J. R., Zhao, P., Ansari, M. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2635 · Cited by 83
Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
Barros, F., Powe, D. G., Ellis, I. O., & Green, A. R. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03494.x · Cited by 83
Millanta, F., Calandrella, M., Citi, S., Santa, D. D., & Poli, A. (2005) · Veterinary Pathology · doi:10.1354/vp.42-1-30 · Cited by 84
Metadata
- Authors
- Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., & Press, M.
- Affiliations
- University of Southern California (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2002-02-01
- Volume
- 20
- Issue
- 3
- Pages
- 719-726
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4239989216
- Cited by
- 1,860
- References
- 9
- Citations by year
- 2026: 12 · 2025: 34 · 2024: 52 · 2023: 75 · 2022: 113 · 2021: 67 · 2020: 72 · 2019: 62 · 2018: 97 · 2017: 95 · 2016: 87 · 2015: 88 · 2014: 71 · 2013: 91 · 2012: 74
- FWCI
- 32.63
- Type
- journal article
- Language
- en
- Update notices
- new_edition (2023-03-15)
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Funders
- National Cancer Institute (CA48780)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- trastuzumab, HER2-positive breast cancer, metastatic breast cancer, first-line therapy, single-agent chemotherapy, HER2 immunohistochemistry, HER2 amplification, objective response rate, adverse cardiac events, dose-response relationship, treatment safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
